“The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting — loss of relevancy» says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.
“The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting — loss of relevancy» says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.